Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous T-Cell Lymphoma
Description
The presentation focuses on cutaneous T-cell lymphoma (CTCL), a group of over 20 diseases marked by diverse clinical manifestations, including mycosis fungoides and Sézary syndrome. The speaker emphasizes the importance of recognizing the clinical features of these conditions, which can often mimic inflammatory skin diseases like psoriasis and atopic dermatitis, leading to diagnostic delays of three to five years. With around 70% of CTCL cases being linked to either mycosis fungoides or Sézary syndrome, awareness of their typical and atypical presentations is essential for accurate diagnosis. Histological challenges are noted, as dermatopathologists may overlook CTCL if it's not on their differential diagnosis list. The management of CTCL requires a thorough clinical evaluation, blood tests, and skin biopsies, with regular monitoring for early-stage indicators since most patients present with early-stage disease, which generally has a better prognosis. New therapies, including targeted biologics and combination treatments tailored to specific disease compartments, show promise. Current research is improving understanding of CTCL pathogenesis and developing tailored treatments, though some patients still experience tumor progression and treatment resistance. The need for increased awareness and understanding among clinicians is emphasized, and the speaker encourages participation in ongoing research and educational initiatives within the field.
View moreConclusions
- Cutaneous lymphoma often mimics inflammatory skin diseases, leading to diagnostic delays.
- Clinical presentations of cutaneous T-cell lymphomas, like mycosis fungoides and Sézary syndrome, can vary significantly.
- Histological features of cutaneous lymphomas can be nonspecific, complicating definitive diagnosis.
- A substantial percentage of cutaneous lymphoma cases may be misdiagnosed as atopic dermatitis or other inflammatory conditions.
- Cytokine pathway blockers used for treating other skin conditions may exacerbate cutaneous lymphoma symptoms.
- Early-stage cutaneous lymphoma shows a better prognosis with the majority of patients remaining in this category.
- Advanced cutaneous lymphoma is harder to treat and presents with more severe prognosis due to its potentially aggressive nature.
- A multidisciplinary approach is essential for accurate diagnosis and effective treatment of cutaneous lymphomas.
- Current research is focused on targeted therapies and improving diagnostic methods for cutaneous lymphomas.
- Awareness and education among healthcare providers are necessary to prevent misdiagnoses and ensure timely treatment interventions.
- Dai J et al. JAMA Dermatol. 2017
- Jonak C et al, JDDG 2021
- Saulite I et al. Biomed Res Int. 2016
- Mangold AR, et al. J Am Acad Dermatol 2017
- Roenneberg S et al. J Eur Acad Dermatol Venereol. 2023
- Bobrowicz et al. Int Arch Allergy Immunol. 2020
- Olsen EA, et al. Blood. 2022
- Agar NS et al. J Clin Oncol 2010
- Scarisbrick JJ et al. J Clin Oncol. 2015
- Willemze R, et al. Ann Oncol. 2018
- Latzka J et al. Eur J Cancer. 2023
- Gilson D, et al. Br J Dermatol. 2019
- Khodadoust MS, Mou E, Kim YH. Blood. 2023
- Watanabe R et al. JAMA Dermatology. 2014
- de Masson A et al. BJD. 2014
- Scarisbrick J et al. Eur. J. Cancer. 2022
- Chnag YT et al. Nat. Communications 2024
- Tsai YC et al. (2023) Br J Dermatol
- Iselin C. et al. (2021) Oncoimmunology
- Pavlova O et al. J Invest Dermatol. 2023
- Bernard P & Guenova E. J Eur Acad Dermatol Venereol. 2024